Skip to main content
63°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
5.390
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Revance to Participate in Upcoming Investor Conferences
November 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
November 01, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
October 26, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Analyst Ratings for Revance Therapeutics
October 11, 2023
Via
Benzinga
The Latest Analyst Ratings for Revance Therapeutics
September 20, 2023
Via
Benzinga
What's Going On With Botox Rival Revance Therapeutics' Stock Today?
September 19, 2023
Revance Therapeutics Inc (NASDAQ: RVNC) commenced a plan to exit the
Via
Benzinga
Where Revance Therapeutics Stands With Analysts
August 09, 2023
Via
Benzinga
Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions
September 20, 2023
Needham analyst Serge Belanger reiterated a Buy rating on Revance Therapeutics, Inc. (NASDAQ: RVNC),
Via
Benzinga
Pinterest To Rally Around 45%? Here Are 10 Other Analyst Forecasts For Wednesday
September 20, 2023
Rosenblatt increased the price target for Pinterest, Inc. (NYSE: PINS) from $35 to $38. Rosenblatt analyst Barton Crockett maintained a Buy rating. Pinterest shares rose 3.2% to close at $26.21 on...
Via
Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
September 20, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.
Via
Benzinga
Instacart, ARS Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
September 20, 2023
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Earnings Preview: Revance Therapeutics
August 07, 2023
Via
Benzinga
Dow Falls 150 Points; AutoZone Earnings Top Views
September 19, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 150 points on Tuesday. The Dow traded down 0.48% to 34,457.36 while the NASDAQ fell 0.28% to 13,672.29. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stocks That Hit 52-Week Lows On Tuesday
September 19, 2023
During Tuesday's session, 275 companies made new 52-week lows.
Via
Benzinga
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 19, 2023
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday.
Via
Benzinga
Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
September 19, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones falling more than 200 points on Tuesday. The Dow traded down 0.69% to 34,384.29 while the NASDAQ fell 0.82% to 13,597.78. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
September 19, 2023
The company is still figuring out how to gain share in a market topped by AbbVie.
Via
Investor's Business Daily
Markets Open Lower; US Housing Starts Fall In August
September 19, 2023
U.S. stocks traded lower this morning, with the Dow Jones falling around 40 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.12% to 34,581.70 while the NASDAQ fell 0.33%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Revance Provides Corporate Update at Investor Day
September 19, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.
Via
InvestorPlace
3 Very Oversold Biotech Stocks to Buy Right Now
August 29, 2023
These biotech stocks have tumbled a great deal in recent months, but their long-term outlooks remain quite strong.
Via
InvestorPlace
3 Very Oversold Pharma Stocks to Buy Right Now
August 24, 2023
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Monday
September 11, 2023
Monday's session saw 175 companies set new 52-week lows.
Via
Benzinga
Revance to Host Investor Day on September 19, 2023
August 22, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
September 08, 2023
Friday's session saw 225 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
August 16, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
On Thursday, 283 companies set new 52-week lows.
Via
Benzinga
How Revance Is Taking A Page Out Of AbbVie's Botox Playbook
August 14, 2023
The company sells a cosmetic treatment. Now, it's bridging into neuroscience.
Via
Investor's Business Daily
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
August 14, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
August 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.